Developing next generation cell and protein therapeutics for fatal diseases

AdAlta (ASX:1AD) is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers.

AdAlta’s “East to West” cellular immunotherapy strategy is the primary driver of future growth and value creation initiatives. This strategy is seeing the Company integrate Asia’s innovation in T cell therapy development with the efficiency and quality of Australia’s clinical and manufacturing ecosystem to create a pathway connecting ‘Eastern’ innovation in cellular immunotherapies with ‘Western’ regulated markets and patients.

AdAlta has previously developed drug candidates using its proprietary i-body technology. AD-214 takes a whole new approach to fibrotic diseases. AdAlta is seeking external strategic and financial partners to continue development of AD-214 into Phase II clinical trials. WD-34 is the first anti-body like molecule to inhibit malaria parasite invasion of human cells for all strains of malaria. AdAlta is seeking grant financing and external partners to establish a single treatment format for seasonal protection. Transactions will effectively monetise the value created by AdAlta’s R&D spend to date.